Aleks Engel Ph.D Overview
- Firm
- Novo Holdings
- Primary Position
-
Partner, Planeta...
- Primary Industry
-
Healthcare
- Active Board Seats
-
2
- Med. Deal Size
-
- Med. Valuation
-
Aleks Engel Ph.D General Information
Biography
Dr. Aleks Engel serves as Partner, Planetary Health Investments at Novo Holdings. Prior to joining Novo Holdings, Dr. Engel was employed as VP in Baxter International in Illinois and Shanghai, working with global M&A licensing, growth strategies, investment prioritization and go-to-market planning. Other previous employments include Pfizer Global Research and Development, Thomson Scientific & Healthcare and McKinsey & Company (all U.S.A.). Aleks holds a PhD in Biochemical Engineering and a MSc in Chemical Engineering Practice from Massachusetts Institute of Technology.
Contact Information
Address
- Tuborg Havnevej 19
- 2900
- 2900 Hellerup
- Denmark
Aleks Engel Ph.D Positions (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Novo Holdings | Investor | Partner, Planetary Health Investments | Hellerup, Denmark | Corporate Venture Capital |
Aleks Engel Ph.D Board Seats (2)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
Bactolife | Biotechnology | Privately Held (backing) | Venture Capital-Backed | Copenhagen, Denmark | |
Symphogen | Biotechnology | Acquired/Merged (Operating Subsidiary) | Formerly VC-backed | Ballerup, Denmark |
Aleks Engel Ph.D Lead Partner on Deals (10)
Aleks Engel Ph.D has been the lead partner on 10 deals. Their latest deal was with Benchmark Genetics, a aquaculture company. The deal was made for on 25-Nov-2024.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
Benchmark Genetics | 25-Nov-2024 | Merger/Acquisition | Announced/In Progress | Aquaculture | Bergen, Norway | |
Revagenix | 05-Jan-2024 | Completed | Drug Discovery | San Francisco, CA | ||
Paratek Pharmaceuticals | 21-Sep-2023 | Completed | Pharmaceuticals | King of Prussia, PA | ||
Bactolife | 08-Aug-2023 | Completed | Biotechnology | Copenhagen, Denmark | ||
AFYX Therapeutics | 24-Jun-2019 | Completed | Drug Delivery | Copenhagen, Denmark | ||
Symphogen | 22-Oct-2015 | Completed | Biotechnology | Ballerup, Denmark | ||
Symphogen | 08-Jan-2006 | Completed | Biotechnology | Ballerup, Denmark | ||
Symphogen | 02-Nov-2004 | Completed | Biotechnology | Ballerup, Denmark | ||
Symphogen | 23-Jan-2002 | Early Stage VC (Series A) | Completed | Biotechnology | Ballerup, Denmark | |
Symphogen | 01-Jan-2000 | Seed Round | Completed | Biotechnology | Ballerup, Denmark |
Aleks Engel Ph.D Network (154)
Board Members (40)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Jens Hansen Ph.D | AFYX Therapeutics | AFYX Therapeutics | Copenhagen, Denmark | |
Steen Riisgaard | Xellia Pharmaceuticals | Novo Holdings | Copenhagen, Denmark | |
Xellia Pharmaceuticals | Self | Copenhagen, Denmark | ||
Xellia Pharmaceuticals | Self | Copenhagen, Denmark | ||
Symphogen | Gilde Healthcare | Ballerup, Denmark |
Portfolio Executives (66)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
Malcolm Pye | Benchmark Genetics | Chief Customer Officer | 25-Nov-2024 | Bergen, Norway |
Hideyoshi Segovia | Benchmark Genetics | General Manager | 25-Nov-2024 | Bergen, Norway |
Benchmark Genetics | Acting Chief Financial Officer | 25-Nov-2024 | Bergen, Norway | |
Benchmark Genetics | Finance Manager | 25-Nov-2024 | Bergen, Norway | |
Benchmark Genetics | General Manager | 25-Nov-2024 | Bergen, Norway |
Fund Team Members (48)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Robert Ghenchev | Novo Holdings | Repair Impact Fund | Hellerup, Denmark |
Robert Ghenchev | REPAIR Impact Fund | Repair Impact Fund | Hellerup, Denmark |
Novo Holdings | Hellerup, Denmark | ||
REPAIR Impact Fund | Hellerup, Denmark | ||
Novo Holdings | Hellerup, Denmark |
Aleks Engel Ph.D Affiliated Funds (3)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
Repair Impact Fund | Novo Holdings | Venture Capital - Early Stage | Closed | 2018 | ||||
Novo Ventures 1 | Novo Holdings | Venture - General | Closed | 2013 | ||||
Novo Seeds | Novo Holdings | Venture Capital - Early Stage | Evergreen |
Aleks Engel Ph.D FAQs
-
Who is Aleks Engel Ph.D?
Dr. Aleks Engel serves as Partner, Planetary Health Investments at Novo Holdings.
-
How much does Aleks Engel Ph.D typically invest?
Aleks Engel Ph.D's median deal size is
. -
What is Aleks Engel Ph.D’s main position?
Aleks Engel Ph.D’s primary position is Partner, Planetary Health Investments.
-
How many active board seats does Aleks Engel Ph.D hold?
Aleks Engel Ph.D holds 2 board seats including Bactolife and Symphogen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »